For example, approximately 20% of AI-resistant breast tumors exhibit mutations in the ERα-encoding gene, while approximately 15% of breast tumors exhibit resistance to anti-E2 therapy owing to downregulated ERα expression [72,73]. This evidence concerns the gene ESR1 and breast neoplasm.